Literature DB >> 1087549

Extrahepatic biliary atresia versus neonatal hepatitis. Review of 137 prospectively investigated infants.

A P Mowat, H T Psacharopoulos, R Williams.   

Abstract

In a prospective regional survey of neonatal hepatitis syndrome 32 infants had extrahepatic biliary atresia (EHBA) and 103 had hepatitis. No cause for the lesion was found in infants with extrahepatic biliary atresia, but in 32 with hepatitis a specific cause was identified, 24 having genetic deficiency of the serum protein alpha1-antitrypsin. No differences were observed in parental age, mother's health in pregnancy, month of birth, birth order, or sex of the infants. Familial idiopathic hepatitis occurred in 3 of 67 sibs of patients with idiopathic hepatitis, but the 33 sibs of EHBA patients had no liver disease. Of the infants with hepatitis, 36 were of low birthweight, less than 2.5 kg, and 23 were born prematurely. Infants with biliary atresia were all of normal birthweight and only one was born prematurely. Consideration of clinical and biochemical abnormalities in the first 2 months of life showed no differences between the two groups except that infants with EHBA were more commonly jaundiced from birth (80%) and had more frequently acholic stools (83%). The frequency of these features in patients with hepatitis being 68% and 52%. Standard tests of liver function were not discriminatory. Percutaneous liver biopsies were diagnostic in 75% of those with EHBA and in 92% of those with hepatitis. The I131 Rose Bengal faecal excretion was less than 10% in 26 of 28 infants with EHBA and in only 5 of 18 with hepatitis. These latter two investigations together allowed a correct preoperativer diagnosis of EHBA in all instances. Bile drainage was achieved surgically in only 3 cases. A major reason for these poor results may have been the late referral of cases for diagnosis and laparotomy, which should be performed as soon as the diagnosis is suspected and always by 70 days of age.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 1087549      PMCID: PMC1546120          DOI: 10.1136/adc.51.10.763

Source DB:  PubMed          Journal:  Arch Dis Child        ISSN: 0003-9888            Impact factor:   3.791


  19 in total

1.  The differential diagnosis of neonatal hepatitis and biliary atresia.

Authors:  D P Campbell; J R Poley; P Alaupovic; E I Smith
Journal:  J Pediatr Surg       Date:  1974-10       Impact factor: 2.545

2.  Extrahepatic biliary atresia: the frequency of potentially operable cases.

Authors:  D M Danks; P E Campbell; A M Clarke; P G Jones; J R Solomon
Journal:  Am J Dis Child       Date:  1974-11

3.  Differentiation between neonatal hepatitis and biliary atresia by measuring serum-alpha-fetoprotein.

Authors:  P M Zeltzer; R C Neerhout; E W Fonkalsrud; E R Stiehm
Journal:  Lancet       Date:  1974-03-09       Impact factor: 79.321

4.  Racial influence on the incidence of biliary atresia.

Authors:  W K Shim; M Kasai; M A Spence
Journal:  Prog Pediatr Surg       Date:  1974

5.  Twenty-five-year survival aftery surgery for complete extrahepatic biliary atresia. A case report.

Authors:  M M Berenson; A R Garde; F G Moody
Journal:  Gastroenterology       Date:  1974-02       Impact factor: 22.682

6.  Experience in the management of surgically correctable biliary atresia.

Authors:  E Arima; E W Fonkalsrud; R C Neerhout
Journal:  Surgery       Date:  1974-02       Impact factor: 3.982

7.  Hepatic portoenterostomy--is it indicated in the treatment of biliary atresia?

Authors:  D P Campbell; J R Poley; M Bhatia; E I Smith
Journal:  J Pediatr Surg       Date:  1974-06       Impact factor: 2.545

8.  Considerations of the pathogenesis of neonatal hepatitis, biliary atresia and choledochal cyst--the concept of infantile obstructive cholangiopathy.

Authors:  B H Landing
Journal:  Prog Pediatr Surg       Date:  1974

9.  Follow-up studies of long term survivors after hepatic portoenterostomy for "noncorrectible" biliary atresia.

Authors:  M Kasai; I Watanabe; R Ohi
Journal:  J Pediatr Surg       Date:  1975-04       Impact factor: 2.545

10.  1 -Antitrypsin deficiency and neonatal hepatitis.

Authors:  C A Porter; A P Mowat; P J Cook; D W Haynes; K B Shilkin; R Williams
Journal:  Br Med J       Date:  1972-08-19
View more
  30 in total

Review 1.  Liver disease in infancy: a 20 year perspective.

Authors:  G Mieli-Vergani; E R Howard; A P Mowat
Journal:  Gut       Date:  1991-09       Impact factor: 23.059

2.  Biliary atresia in childhood.

Authors:  A P Mowat; E R Howard
Journal:  Br Med J       Date:  1977-05-14

Review 3.  Managing biliary atresia.

Authors:  R Nelson
Journal:  BMJ       Date:  1989-06-03

Review 4.  Extrahepatic biliary atresia. Recent developments in management.

Authors:  E R Howard; A P Mowat
Journal:  Arch Dis Child       Date:  1977-11       Impact factor: 3.791

5.  Neonatal malaria and obstructive jaundice.

Authors:  M Davenport
Journal:  Arch Dis Child       Date:  1986-05       Impact factor: 3.791

6.  Changing pattern of chronic liver disease (CLD) in India.

Authors:  S Bhave; A Bavdekar; A Pandit
Journal:  Indian J Pediatr       Date:  1994 Nov-Dec       Impact factor: 1.967

7.  Clinical Assessment of Differential Diagnostic Methods in Infants with Cholestasis due to Biliary Atresia or Non-Biliary Atresia.

Authors:  Chen Dong; Hui-Yun Zhu; Yun-Chao Chen; Xiao-Ping Luo; Zhi-Hua Huang
Journal:  Curr Med Sci       Date:  2018-03-15

8.  Biopsy-driven diagnosis in infants with cholestatic jaundice in Iran.

Authors:  Elham Talachian; Ali Bidari; Mitra Mehrazma; Nahid Nick-khah
Journal:  World J Gastroenterol       Date:  2014-01-28       Impact factor: 5.742

9.  A long-term experience with biliary atresia. Reassessment of prognostic factors.

Authors:  D U Tagge; E P Tagge; R A Drongowski; K T Oldham; A G Coran
Journal:  Ann Surg       Date:  1991-11       Impact factor: 12.969

10.  Alpha-1-antitrypsin phenotypes in adult liver disease patients.

Authors:  Aleksandra Topic; Tamara Alempijevic; Aleksandra Sokic Milutinovic; Nada Kovacevic
Journal:  Ups J Med Sci       Date:  2009       Impact factor: 2.384

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.